286-Myeloid-Targeted Immunocytokines
This article details the development and preclinical testing of a novel cancer immunotherapy called MiTEs (myeloid-targeted immunocytokines and natural killer (NK)/T cell enhancers). The researchers engineered MiTEs to overcome the immunosuppressive tumor microenvironment by simultaneously targeting Tumor-Associated Macrophages (TAMs) and activating effector lymphocytes (T and NK cells). Specifically, MiTEs are masked IL-2 cytokines fused to an antagonistic anti-TREM2 antibody, ensuring the toxic IL-2 component is only activated within the tumor by a TAM-specific protease, MMP14. Extensive…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.